Optimizing Oncology Generic Medication Selection in the Gulf Region: Expert Consensus and MCDA Tool Development.

Area of Science:

• Oncology
• Pharmacoeconomics
• Health Policy

Background:

• Cancer poses a significant global health burden.
• Generic oncology drugs present a cost-effective alternative to patented treatments in GCC countries.
• Barriers to generic oncology drug adoption include regulatory disparities and concerns over quality and supply.

Purpose of the Study:

• To evaluate key factors influencing the selection of off-patent oncology drugs in GCC countries.
• To develop a structured framework for assessing generic oncology drug formulary decisions.

Main Methods:

• Multicriteria decision analysis (MCDA) was employed.
• A structured survey and workshop were conducted with 10 formulary management experts from UAE, Qatar, Kuwait, Bahrain, and Oman.
• Experts prioritized decision-making criteria through guided discussions, case studies, and weighting surveys.

Main Results:

• Manufacturing quality (30.8%), cost (20%), and use in reference countries (14.6%) were the most critical selection factors.
• Supply reliability (13%), regulatory aspects (8%), and pharmacovigilance/extra services (6.8% each) were also important.
• A structured evaluation framework for formulary decisions in the GCC region was developed.

Conclusions:

• An expert consensus highlights the need for a balanced approach to ensure quality, affordability, and accessibility of oncology generics.
• Strengthening regulatory frameworks, pharmacovigilance, and stakeholder education is crucial for optimal integration.
• Findings support policy recommendations to improve generic drug adoption and patient outcomes in oncology care.